403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Turkish Abdi Ibrahim purchases 28.5 percent of Swiss OM Pharma
(MENAFN) Foremost Turkish pharmaceutical Abdi Ibrahim on September 18 declared that it had purchased 28.5 percent of the shares of Swiss-based biotech corporation OM Pharma for 4.2 billion liras (530 million USD).
A company statement showed that the attainment made Abdi Ibrahim the first and only Turkish pharmaceutical to outline a planned partnership with a European equivalent.
Nezih Barut the company chairman stated that "The partnership, and especially our biotech products, will facilitate our access to new markets, particularly Latin America, China, and the US,".
Similarly, OM Pharma, Barut added that will at the present have easier admission to the Middle East and North Africa, where Abdi Ibrahim enjoys a important attendance.
A company statement showed that the attainment made Abdi Ibrahim the first and only Turkish pharmaceutical to outline a planned partnership with a European equivalent.
Nezih Barut the company chairman stated that "The partnership, and especially our biotech products, will facilitate our access to new markets, particularly Latin America, China, and the US,".
Similarly, OM Pharma, Barut added that will at the present have easier admission to the Middle East and North Africa, where Abdi Ibrahim enjoys a important attendance.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment